AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

The boss of drugmaker AstraZeneca was handed a pay package worth nearly £15m last year, new company accounts reveal.

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.